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Abstract
Background: The impressive correlation between cardiovascular disease and glucose metabolism
alterations has raised the likelihood that atherosclerosis and type 2 diabetes may share common
antecedents. Inflammation is emerging as a conceivable etiologic mechanism for both. Interleukins
are regulatory proteins with ability to accelerate or inhibit inflammatory processes.
Presentation of the hypothesis: A novel interleukins classification is described, based on their
role in diabetes and atherosclerosis, hypothesizing that each interleukin (IL) acts on both diseases
in the same direction – regardless if harmful, favorable or neutral.
Testing the hypothesis: The 29 known interleukins were clustered into three groups: noxious
(the "bad", 8 members), comprising IL-1, IL-2, IL-6, IL-7, IL-8, IL-15, IL-17 and IL-18; protective (the
"good", 5 members), comprising IL-4, IL-10, IL-11, IL-12 and IL-13; and "aloof", comprising IL-5, IL-
9, IL-14, IL-16 and IL-19 through IL-29 (15 members). Each group presented converging effects on
both diseases. IL-3 was reluctant to clustering.
Implications: These observations imply that 1) favorable effects of a given IL on either diabetes
or atherosclerosis predicts similar effects on the other; 2) equally, harmful IL effects on one disease
can be extrapolated to the other; and 3) absence of influence of a given IL on one of these diseases
forecasts lack of effects on the other. These facts further support the unifying etiologic theory of
both ailments, emphasizing the importance of a cardiovascular diabetologic approach to
interleukins for future research. Pharmacologic targeting of these cytokines might provide an
effective means to simultaneously control both atherosclerosis and diabetes.
Background
The impressive correlation between coronary artery dis-
ease (CAD) and alterations in glucose metabolism has
raised the likelihood that atherosclerosis and type 2 dia-
betes may share common antecedents. It is now known
that adverse environmental conditions – perhaps related
to less-than-optimal nutrition – in fetal and early life are
associated with an enhanced risk of both diabetes and car-
diovascular disease many decades later. Large-vessel
atherosclerosis can precede the development of diabetes,
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suggesting that rather than atherosclerosis being a compli-
cation of diabetes, both conditions may share genetic and
environmental antecedents, a "common soil" [1]. These
same adverse environmental conditions associated with
hyperinsulinemia and insulin resistance lead to the devel-
opment in adult life of the dysmetabolic syndrome, con-
sisting of abdominal obesity, impaired fasting glucose,
high triglyceride levels, low high-density lipoprotein lev-
els and hypertension. These constituents may be associ-
ated with additional elements, such as elevations in small
low-density lipoproteins, prothrombotic factors and free
fatty acids [2]. Taking into consideration that the compo-
nents of this cluster of abnormalities are essentially shared
by both diabetes type 2 and atherosclerosis, the American
Heart Association stated in 1999 that "diabetes is a cardi-
ovascular disease" [3]. Although the mechanism underly-
ing this cluster is not yet fully clarified, the statistical
association is well established [1].
In this context, chronic low-grade inflammation is emerg-
ing as a conceivable etiologic mechanism. Inflammation
plays an important role in mediating all phases of athero-
sclerosis, from initial recruitment of circulating cells to the
inner arterial layer to weakening of the fibrous cap of the
plaque, eventually leading to rupture. Inflammation is
heavily involved in the onset and development of athero-
thrombotic disease, which is accompanied by the emer-
gence of numerous inflammatory biomarkers. Such
biomarkers comprise a vast array of substances, including
cytokines as the interleukins, acute phase proteins, adhe-
sion molecules, tumor necrosis factor (TNF) and mono-
cyte chemoattractant protein (MCP) isoforms,
interferons, chemokines, etc [4]. Several studies have
demonstrated an association between these biomarkers
and current or future overt CAD [5–7]. A close relation is
also present between the biomarkers and glucose metabo-
lism abnormalities. For instance, obese patients with
impaired fasting glucose exhibit elevated concentrations
of interleukin (IL)-8 [8], glucose increases monocyte
adhesion to human aortic endothelial cells via stimula-
tion of IL-8 [9], and elevated levels of IL-18 and TNF-α
were found in serum of patients with type 2 diabetes mel-
litus [10]. Thus, a common inflammatory basis for both
diabetes and CAD seems plausible [11].
Presentation of the hypothesis
Interleukins are probably the most extensively produced
biomarkers. Considerable confusion exists regarding their
clinical value, due to several factors: 1) increased levels of
a given IL, presenting statistical correlation with disease,
does not necessarily imply causation; 2) these compounds
are characterized by substantial redundancy in that differ-
ent interleukins have similar functions; 3) many of them
are pleiotropic, with capability of acting on different cell
types; 4) interleukins may stimulate secretion of other
interleukins, enhancing or inhibiting each other; 5) inter-
leukins possess "paradoxical" effects, expressed as protec-
tive properties regarding a given system, whereas they may
damage another system; 6) protective or noxious effects of
a given interleukin may be concentration-dependent.
A huge quantity of data regarding interleukins has been
accumulating during the last two decades; a considerable
part is dedicated to their effects on diabetes and cardiovas-
cular function. However, no attempts have been made to
present a systematic classification of interleukins based on
their influences on these systems. Several essential ques-
tions remain yet unanswered: 1) does a favorable or harm-
ful effect of a given IL on diabetes necessarily imply
similar effects on atherosclerosis? 2) conversely, can the
interleukins effects on atherosclerosis be extrapolated to
diabetes? 3) can the absence of IL activity on one of these
diseases predict lack of effects on the other?
We will try to answer to these questions, describing a
novel interleukins classification based on their role in dia-
betes and cardiovascular disease. Taking into account the
alleged common inflammatory venue of these conditions,
we hypothesize that the effects of each of the interleukins
on both disorders will probably be moving in the same
direction – regardless if harmful, favorable or neutral. If
corroborated, this hypothesis could represent an addi-
tional step in building a unifying theory regarding the
inflammatory basis of both type 2 diabetes and
atherosclerosis.
Testing the hypothesis
Interleukins: how to define, how to classify
Interleukins are a wide spectrum of small regulatory pro-
tein molecules encompassed in the family of cytokines,
exerting their effects via gene activation that leads to cellu-
lar stimulation, growth, differentiation, functional cell-
surface receptor expression, and cellular effector function.
In this regard, interleukins may exhibit marked effects on
the regulation of immune responses and the pathogenesis
of a great variety of diseases. Indeed, T cells have been cat-
egorized on the basis of the pattern of the interleukins that
they secrete, resulting in either a cell-mediated immune
response (TH1) or a humoral immune response (TH2)
[12].
The interleukins are produced by a great variety of cells,
mainly monocytes, macrophages, neutrophils, T-cells,
mast cells, eosinophils. However, it must be pointed out
that this is only a partial list. Endothelial and epithelial
cells, fibroblasts, smooth muscle cells, neuronal cells,
tumoral cells, etc, represent additional sources. Inter-
leukins were cloned two decades ago and since then new
members have been discovered in an ever-increasingCardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/11
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number, the latest being the recently described IL-28 and
IL-29 [13].
Attempts for grouping the interleukins according to pre-
defined parameters may be done on the basis of the loca-
tion of their activity. Thus, employing a site-based
classification, interleukins are defined as
1) Autocrine: acting on the same cell that secretes the IL,
like IL-10.
2) Paracrine: acting on a cell located in an adjacent zone,
like IL-12.
3) Endocrine: secreted into the general circulation and act-
ing far from its source, like IL-11.
This classification, while presenting some tutorial value, is
imperfect because several interleukins overlap these
categories.
Another possibility is to classify these compounds taking
into account their biochemical influences. This generates
a role-based classification, according to which inter-
leukins will be
1) Proinflammatory: secreted mainly by mononuclear
phagocytes in response to infectious agents, such as IL-1,
IL-6 and IL-8.
2) Immunoregulatory: involved in the activation, growth,
and differentiation of lymphocytes and monocytes, like
IL-2, IL-4 and IL-10.
3) Leukocyte developmental: regulating immature white
cell growth and differentiation; IL-3 and IL-7 represent
this category.
This approach is also somewhat problematic, since it is
more semantic than physiological. The term interleukin
maybe haphazard in some cases. For instance, IL-2 was
formerly known as "T-cell growth factor" and IL-11 as
"adipogenesis inhibitory factor" [14]. On the other hand,
several agents – like TNF-α1, the monocyte chemoattract-
ant protein (MCP) isoforms and the transforming growth
factor-β – whose functions are similar to those of inter-
leukins, are not regarded as such. Thus, this nomenclature
may be arbitrary.
From the standpoint of diabetes and cardiovascular med-
icine, the main concern with both the site-based and the
role-based classifications is their lack of clinical signifi-
cance. A practical approach would be to look at inter-
leukins considering their influence on these systems –
defined as benefit or damage – in the framework of an
inflammatory process. This would be a yield-based classi-
fication, and in our opinion, preferable. Like the former
classifications, it allows definition of 3 categories:
1) Noxious (the "bad"): interleukins provoking a cascade
of events ensuing in development of macrophages and
foam cells, fatty streak formation and ultimately stable or
unstable fibrous plaque. Proinflammatory stimuli such as
oxidatively modified low density lipoprotein cholesterol,
free radicals, cigarette smoking, elevated plasma homo-
cystein and infections, cause endothelial dysfunction
leading to compensatory responses which alter the nor-
mal properties of the endothelium. This cascade of events
is mediated by proinflammatory and chemoattractant
interleukins produced by activated inflammatory, vascu-
lar smooth muscle and endothelial cells. The fatty streak
is the earliest manifestation of atherosclerosis, consisting
mainly of monocyte-derived macrophages and T-lym-
phocytes [15]. The noxious interleukins also show a con-
sistent relation to diabetes via glucose regulation of
monocyte adhesion [9] alongside etiopathogenic roles
and increased genetic susceptibility to diabetic nephropa-
thy [10,16].
2) Protective (the "good"): interleukins representing a
restraint for the development and progression of the
atherothrombotic process. These compounds are involved
in inhibition of proinflammatory agents production by
activated monocytes or macrophages, suppression of IL-1,
TNF-α and other cytokine activities, inhibition of matrix
degrading MMP isforms, reduction of tissue factor expres-
sion and inhibition of apoptosis of macrophages and
monocytes after infection. In addition, in diabetic experi-
mental models, administration of protective interleukins
results in maintenance of euglycemia even in the absence
of insulin [17].
3) Aloof: this group includes interleukins whose influ-
ences on the cardiovascular system and on glucose metab-
olism are practically indifferent or not yet fully
established.
The members of each of these groups are depicted in Fig-
ure 1 and described in the following sections.
The "bad": noxious interleukins
This group comprises eight members: IL-1, IL-2, IL-6, IL-7,
IL-8, IL-15, IL-17 and IL-18.
IL-1 is a glycoprotein existing in two major biologically
active isoforms, the predominantly membrane-bound IL-
1α and the secreted IL-1β. Of these, IL-1β is the principally
circulating isoform. Monocytes, macrophages and macro-
phage-derived foam cells are the main sources of IL-1, but
it is also produced by others such as endothelial cells [18].Cardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/11
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IL-1 mediates the inflammatory response occurring in the
vascular wall during atherogenesis by activating mono-
cytes and expression of adhesion molecules on endothe-
lial cells, inducing secretion of other cytokines,
chemokines and growth factors and stimulating smooth
muscle cell proliferation [18]. It also induces coagulation
[14]. As a key mediator of inflammation, IL-1 is plays a
major role in the pathogenesis of CAD. Increased synthe-
sis of IL-1 has been demonstrated in human arterial
plaques [19], and serum concentrations of IL-1β are raised
in patients with even minimal CAD [20]. In addition, IL-
1β has deletereous effects on pancreatic islets and insulin-
secreting β-cell lines. It is well established that it inhibits
β-cell function and is cytotoxic to human and rodent pan-
creatic islets in vitro [21].
IL-2 is a T-cell derived cytokine involved in the activation,
growth, and differentiation of a variety of cells, including
lymphocytes and monocytes. Attempting to determine
the relationship between T-lymphocyte activation and
CAD by measuring plasma levels of cytokines related to T-
lymphocyte function in coronary patients, high levels of
IL-2 and soluble IL-2 receptor were found in those with
stable but not unstable angina [22]. It plays also a role in
experimental diabetes. The nonobese diabetic mouse
strain spontaneously develops autoimmune diabetes,
which is characterized by insulitis, followed by selective
destruction of β-cells in pancreatic islets. Evidence sug-
gests that this β-cell destruction is mediated in part by IL-
2; this cytokine was necessary and sufficient to direct naive
T cells into the TH1 lineage [23].
IL-6 is a secondary multifunctional proinflammatory
cytokine. It regulates humoral and cellular responses and
plays a central role in inflammation and tissue injury. Its
effects are mediated through interaction with its receptor
complex, IL-6R. This cytokine plays a very important role
in the pathogenesis of CAD. Large quantities of IL-6 are
found in human atherosclerotic plaques [24]. IL-6 levels
appear to be predictive of future CAD [25] and is elevated
in patients with unstable angina compared with those
with stable angina [26]. Patients with persistently elevated
IL-6 levels demonstrate a worse in-hospital outcome fol-
lowing admission with unstable angina [27,28]. IL-6 also
plays a role in diabetes. It has been shown that postmen-
opausal women with type 1 diabetes present higher serum
bioactive IL-6 levels than matched healthy controls [29].
Moreover, IL-6 polymorphism seems to be a genetic sus-
ceptibility factor for the progression of diabetic nephrop-
athy [16].
Recent data suggest a role for IL-7-driven inflammation in
atherogenesis and the promotion of clinical instability in
CAD involving interactions between platelets, monocytes,
and chemokines [30]. This is based on the fact that its
plasma levels were significantly increased in patients with
stable, and – particularly – unstable angina compared to
healthy controls; increased release from activated platelets
appeared to be a major contributor to raised IL-7 levels in
patients with angina. In addition, IL-7 enhanced the
expression of several inflammatory chemokines in
peripheral blood mononuclear cells in both healthy sub-
jects and patients with CAD, and aspirin reduced both
spontaneous and stimulated release of IL-7 from platelets
[30]. Concerning diabetes, IL-7 is suggested to function
through IL-2 production on mature T-cells [14], which
can lead to β-cell destruction.
IL-8 is a chemokine, or chemoattractant cytokine. Chem-
okines are members of a superfamily of small polypep-
tides mediating migration, growth and activation of
leukocytes and a variety of other cells [31]. Chemokines
are designated CC and CXC, according to the spacing of
the first two of four conserved cysteine residues. MCP-1 is
the prototype of the CC class, where the first two cysteines
are adjacent, whereas IL-8 and the recently discovered
fractalkine [32] are prototypes for the CXC class, in which
the first two cysteines are separated by a single aminoacid
residue [31]. IL-8 is expressed by macrophages and
released after inflammatory stimuli in response to the pri-
mary cytokines IL-1β and TNF-α. It induces
A cardiovascular diabetologic approach to the 29 known  interleukins Figure 1
A cardiovascular diabetologic approach to the 29 known 
interleukins. The noxious interleukins ("bad") are depicted as 
red triangles, the protective ("good") as green circles, and the 
aloof as yellow squares. Interleukin-3 is depicted as a half 
red-half green square due to its ambiguity: albeit "good" in 
terms of glucose metabolism, it was not clustered into this 
group due to its effects on the heart (see text: Curtail of the 
scope).Cardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/11
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chemoattraction of monocytes and activated T-cells and
can induce vascular smooth muscle cell proliferation and
migration. In addition to causing local immune response,
the recruited T-cells along with macrophages occur in
large numbers at the sites of plaque rupture, playing a
major role in atherogenesis [33]. Inflammatory cytokines
secreted by the T-cells are capable of inducing the expres-
sion of several MMP isoforms by macrophages leading to
development of unstable plaques. Moreover, IL-8 and the
soluble form of selectin-P may be useful clinical predic-
tors of unstable CAD (33). Regarding glucose metabo-
lism, monocyte MMP-1, 3, and 9 production are normal
in type 2 diabetes [35], but plasma IL-8 concentrations
after glucose load are increased in obese subjects with
impaired fasting glucose in comparison to normoglyc-
emic weight-matched individuals. These increased levels
may be both insulin-mediated (by clamping) or glucose-
mediated (during glucose tolerance test) [8]. Additionally,
it is well established that glucose itself increases monocyte
adhesion to human aortic endothelial cells [9].
IL-15 is a T cell growth factor that shares many functional
similarities with IL-2, albeit no significant sequence
homologies were found [14]; it has recently been shown
to be present in tissue and organ allografts. IL-15 plays an
important role in the rejection of a vascularized organ
allograft and it was demonstrated that antagonists to IL-
15 may be of therapeutic value in preventing allograft
rejection [36]. In mice models, IL-15 is a cytokine leading
to destructive insulitis, as it elicits TH1-cytotoxic
responses in both lymphoid and nonlymphoid immune
cells and is unusually resistant to downregulation by
antagonistic cytokines [37].
IL-17 is a T cell-derived cytokine that stimulates stromal
cells and macrophages to secrete proinflammatory
cytokines. It may harmfully influence diabetes and
atherosclerosis due to its capability to induce production
of IL-6 and IL-8 [14]. In addition, it plays a role in alloim-
mune responses, shortening the survival of heterotopic
heart transplantation in animals. Interference with this
activity might suppress allograft rejection, representing a
novel target for therapeutic intervention in heart trans-
plant rejection [38]. In fact, IL-17 is a great family of iso-
forms sharing four highly conserved cysteine residues
involved in the formation of intrachain disulfide linkages
[39].
IL-18 – functionally related to IL-1 – is a proinflammatory
cytokine with multiple biologic functions [40]. In concert
with IL-12, IL-18 stimulates TH1 mediated immune
responses. In addition, by itself it can stimulate TH2
cytokine production [40]. IL-18 plays a central role in
orchestrating the cytokine cascade and accelerates athero-
sclerosis and plaque vulnerability in animal models.
Serum IL-18 level was identified as a strong independent
predictor of death from cardiovascular causes in patients
with CAD regardless of the clinical status, strongly sup-
porting recent experimental evidence of IL-18-mediated
inflammation leading to acceleration and vulnerability of
atherosclerotic plaques [41]. Moreover, IL-18 is raised in
heart failure patients, in whom elevations correlate with
poorer cardiac functional class and higher TNF-α concen-
trations. IL-18 appears likely to participate in the patho-
physiology of congestive heart failure [42]. Accumulating
evidence suggests that this activity is supported by proin-
flammatory cytokines such as TNF-α, IL-1β and IL-6.
Cytokine actions directly identified to date include pro-
motion of systemic catabolism, myocardial depression,
cardiac hypertrophy, and apoptosis of myocytes in con-
gestive heart failure [42]. In the context of glucose metab-
olism, preclinical stages of type 1 diabetes are
characterized by infiltrating T cells and by the peri- and
intraislet accumulation of proinflammatory mediators
[43]. Increased IL-18 expression is detected in islets during
advanced stages of insulitis and correlates with elevated
transcripts for interferon-γ and for the IL-18 receptor; the
biological activity of IL-18 is blocked using caspase inhib-
itors and anti-IL-18 antibodies. It is established that beta
cells produce bioactive IL-18 in the course of insulitis and
actively contribute to the exacerbation of inflammation
leading to their own demise [43]. In addition, elevated
levels of interleukin-18 and TNF-α in serum of patients
with type 2 diabetes mellitus correlate with diabetic neph-
ropathy [10].
The "good": protective interleukins
Five constituents are included in this category: IL-4, IL-10,
IL-11, IL-12 and IL-13.
IL-4 is a cytokine of the T-helper 2 (TH2) sub-type, mainly
produced by activated T cells and mast cells. It is a pleio-
tropic cytokine that affects cells of multiple lineages, help-
ing to stimulate antibody production. It possesses a
striking ability to suppress proinflammatory responses
such as IL-1 and TNF-α production [14]. In heart trans-
plant recipients, relatively high frequencies of IL-4-pro-
ducing T cells have a beneficial effect on the outcome,
being associated with less rejection episodes [44]. This is
manifested by IL-4 production within the donor heart,
mainly by mast cells, and also by fibroblasts present in the
donor's stromal elements [45]. Concerning diabetes, chil-
dren with parents with type 1 diabetes demonstrated an
impairment in the ability to produce the IL-4 related
immunoglobulin G4 antibody response to tetanus toxoid
[46]. This is consistent with a protective effect of IL-4 in
early prediabetes [46]. In addition, the combined admin-
istration of IL-4/IL-10 expression plasmids has demon-
strated synergistic effects on the prevention of
autoimmune diabetes. On the cellular level, the chimericCardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/11
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IL-4 and IL-10 expression plasmid can effectively reduce
the incidence of autoimmune insulitis [47].
IL-10 is secreted by activated monocytes/macrophages
and lymphocytes, possessing multifaceted antiinflamma-
tory properties. Its secretion leads to suppressed cytokine
production, to inhibition of MMP isoforms expression,
and to blockage of apoptosis of macrophages and mono-
cytes after infection. All these inflammatory mechanisms
have been shown to play a pivotal role for atherosclerotic
lesion development and progression, suggesting a benefi-
cial regulatory role of IL-10. Indeed, numerous recent
experimental studies have shown that either systemic or
local IL-10 gene transfer not only attenuates atherogene-
sis, but also affects processes associated with lesion pro-
gression [48]. IL-10 is expressed in advanced human
atherosclerosis and is associated with low inducible nitric
oxide synthase expression and low levels of apoptosis,
again suggesting a protective role of this antiinflammatory
cytokine [49]. A reduced IL-10 serum level is not only a
marker of plaque instability favoring the development of
acute coronary syndromes, but more importantly is indic-
ative of a poor prognosis even after the occurrence of an
acute ischemic event caused by plaque instability. In addi-
tion, the beneficial effect of elevated serum levels of IL-10
is restricted to patients with elevated CRP serum levels,
indicative of an enhanced systemic inflammatory
response [48]. With regard to diabetes, experimental stud-
ies using gene-targeted mice [50] provide direct evidence
that IL-10 offers some protection against endothelial dys-
function during diabetes and that this effect is mediated
by inhibition of increases in O2 
- in blood vessels. A source
of this O2 
- may be xanthine oxidase. It was also demon-
strated that endogenous IL-10 is an important counterbal-
ance to mechanisms that produce endothelial dysfunction
during diabetes [50] and that mucosal administration of
IL-10 enhances oral tolerance in both autoimmune
encephalomyelitis and diabetes [51]. These findings sup-
port the concept that IL-10 is also an important protective
molecule in diabetes [49,50].
Scarce data are available regarding the cardiac effects of IL-
11. It was shown that myocytes and fibroblasts isolated
from human atrium are able to secrete IL-6, IL-11 and leu-
kaemia inhibitory factor; IL-11 could be involved in auto-
crine and/or paracrine networks regulating myocardial
cytoprotection [52]. The possibility of direct electrophysi-
ologic effect on single human atrial myocytes was also
considered, but not fully proved [53]. IL-11 presents inter-
esting effects on diabetes, in which the inability of insulin
to properly signal and stimulate the translocation of the
insulin-responsive glucose transporter in muscle, adi-
pocytes and liver leads to hyperglycemia. Adipose tissue
has been identified as a site of synthesis and secretion of
the proinflammatory cytokine TNF-α, which, acting in an
autocrine manner, leads to insulin resistance. In this con-
text, IL-11 emerges as an antiinflammatory cytokine with
receptors located on most cell types and tissues through-
out the body, able to maintain euglycemia in the absence
of insulin in animal models [9].
IL-12 is produced by various immune cells (e.g., mono-
cytes, macrophages, dendritic cells, and neutrophils). It
activates natural killer cells and cytotoxic T-lymphocytes
and induces the production of interferon-gamma. IL-12 is
associated with the cell-mediated immune response. It
has been demonstrated to present protective effects in ani-
mal models of viral myocarditis [54]. This activity is
enhanced by beta blockers, notably carvedilol, conferring
thus a therapeutic benefit by upregulating the production
of IL-12 and interferon gamma and by decreasing the
virus load [54]. Moreover, IL-12 can significantly delay
the rejection of allograft in a neonatal rat heart graft
model, and this effect is mediated by nitric oxide produc-
tion [55]. Initial data indicate a favorable action on glu-
cose metabolism: lymphocyte T activation induced by IL-
12 increases the expression of glucose transporter-like
protein [56].
IL-13 is a cytokine primarily produced by the T-helper-2
subset of lymphocytes that possesses powerful anti-
inflammatory properties. It is synergistic with IL-4, dimin-
ishes insulitis and is capable of downregulating immu-
noinflammatory diabetogenic pathways in nonobese
diabetic mice, and further supports the concept that IL-4-
related anti-inflammatory cytokines might play a role in
the prevention of type 1 diabetes [57]. Regarding its car-
diac aspects, proinflammatory cytokines participate in the
worsening of cardiovascular function during heart failure,
and their high circulating levels are related to the severity
of myocardial dysfunction. Conversely, antiinflammatory
cytokines are believed to exhibit low values in these cases.
In this context, plasma IL-13 was not detected at all in
patients with heart failure [58].
The "aloof" interleukins
This group of 15 includes the majority of interleukins
known at present: IL-5, IL-9, IL-14, IL-16 and IL-19
through IL-29. Substantial effects on glucose metabolism
and cardiovascular system have not been described for
these compounds.
IL-5, IL-9 and IL-16 are related to the respiratory system.
IL-5 is mainly produced by activated T-cells and appears
to be required for the accumulation of eosinophils and
airway hyperresponsiveness in the inflammatory lung
[59]. IL-9 is known to regulate many cell types involved in
T-helper type 2 responses classically associated with
asthma, including B- and T-lymphocytes, mast cells, eosi-
nophils and epithelial cells [60]. IL-16 is a lymphocyteCardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/11
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chemoattractant factor bearing no structural resemblance
to other cytokines or chemokines and its aminoacid
sequence is strongly preserved across species [61]. It is
related to asthma and also able to inhibit human immu-
novirus replication [14].
IL-14 is a high molecular weight B-cell growth factor.
Autocrine or paracrine production of IL-14 may play a sig-
nificant role in the rapid proliferation of non-Hodgkin's
lymphoma [62].
IL-19, IL-20, IL-22 and IL-24 exhibit substantial sharing of
receptor complexes. However, the biological effects of
these four cytokines appear quite distinct: immune activ-
ity with IL-19, skin biology with IL-20, stimulation of pro-
duction of acute-phase reactants with IL-22, and tumor
apoptosis with IL-24 [63]. Despite the fact that they are
structurally closely related to the "good" IL-10, no protec-
tive effects have yet been described.
IL-21 induces the apoptosis of resting and activated pri-
mary B cells [64] and is an hepatocyte-stimulating factor
[65]. Using gene-targeted mice lacking only IL-23, it was
recently demonstrated that IL-23 is the critical cytokine
for autoimmune inflammation of the brain [66]. IL-25 is
derived from TH2 T-cells. Infusion of mice with IL-25
induces IL-4, IL-5, and IL-13 gene expression, suggesting
that IL-25 is capable of amplifying allergic type inflamma-
tory responses by its actions on other cell types [67].
IL-26 is a T-cell-derived cytokine, normally expressed at
low levels but over-expressed after viral infection [13]. IL-
28 and IL-29, distantly related to type I interferons, are
induced by viral infection and show antiviral activity
[13,68].
IL-27 is the newest addition to the "good" IL-12 cytokine
family, presenting specific stimulation on naive CD4+ T
cells in both mice and humans [69], but beneficial effects
on diabetes or heart function were not yet decribed.
Curtail of the scope
It should be noted that the scope on interleukins depicted
in this article presents several restrictions. These include
genetic mapping, description of the numerous isoforms,
characteristics of the IL receptors, general and specific
antimicrobial and antiparasitic activities, role in tumoral
and toxic diseases, etc. These issues were not discussed
since they are beyond the span of this article.
In addition, IL-3 was not included in any of the groups
due to certain ambiguity. IL-3 – a hematopoietic and leu-
kocyte developmental cytokine – shows multilineage col-
ony stimulating factor, augments alloreactive bone
marrow-derived suppressor cell activity in vivo and in
vitro, and is capable of regulating extrathymic T cell devel-
opment from the bone marrow [14,70]. It is a "good" IL
in terms of glucose metabolism, presenting defensive
effects in experimental diabetes. Administration of IL-3
twice weekly starting at 2–4 weeks of age delayed the
onset and reduced the overall incidence of diabetes in
mice. Bone marrow cells obtained from IL-3-treated mice
protected other mice from cyclophosphamide-induced
diabetes [70]. On the other hand, in spontaneously con-
tracting cultured cardiac myocytes, perfusion with IL-3
induced arrhythmias resulting in a complete cessation of
spontaneous contractions and a severe loss of myocyte
inotropy; the effects were concentration-dependent and
reversible [71]. Thus, IL-3 appears to represent a special
case, being the only IL whose effect is incongruous: pro-
tective for diabetes and noxious for the heart. However, it
should be pinpointed that such noxious effects do not
include proinflammatory or atherogenic activities.
Implications of the hypothesis
Atherosclerosis and diabetes present a pleiotropic progres-
sion in which inflammation appears to be a common
background, and patients with diabetes experience accel-
erated atherosclerosis, which has been termed atheroscle-
ropathy [72,73]. Controlling the classical risk factors for
CAD diminishes the incidence of both diseases. However,
these risk factors are only partially successful in identify-
ing many subjects who subsequently develop the ail-
ments. The majority of myocardial infarctions are caused
by coronary lesions presenting less than 50% luminal
obstruction [74]. Moreover, lipid deposition in the
endothelium, per se, does not explain the proliferation of
smooth muscle cells during atherogenesis. These facts her-
ald the concept that the plaque biology may be a very
important determinant of disease outcome. In addition to
the degree of vessel stenosis, biochemical processes within
the plaque – such as those harvested by interleukins – are
now widely recognized as a crucial aspect of stability.
Moreover, sequelae of chronic hyperglycemia, such as oxi-
dative stress and increased protein kinase C production,
are widely invoked as pathogenic mechanisms for acceler-
ated atherosclerosis [75].
Out of the 29 interleukins known at present, only one (IL-
3) shows ambiguous performance and therefore was not
clustered into a group. The other 28 exhibit harmonized
physiologic behavior regarding diabetes and atherosclero-
sis; each one presents converging effects on both diseases.
Eight interleukins are "bad" (IL-1, IL-2, IL-6, IL-7, IL-8, IL-
15, IL-17 and IL-18), five are "good" (IL-4, IL-10, IL-11,
IL-12 and IL-13), and the remaining fifteen are "aloof".
According to this novel yield-based classification, the fol-
lowing implications may be drawn from the standpoint of
cardiovascular diabetology: 1) a favorable effect of a given
IL on either diabetes or atherosclerosis will predict aCardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/11
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similar effect on the other; 2) equally, harmful IL effects
on one disease can be extrapolated to the other; and 3)
absence of influence of a given IL on one of these diseases
forecasts lack of effects on the other.
Several studies report on substantial reductions in the
incidence of type 2 diabetes during pharmacologic inter-
ventions aimed to treat CAD. Such results were observed
with angiotensin converting enzyme inhibitors [76,77]
and statins [78]. Reciprocally, antihyperglycemic agents
like glitazones have shown favorable effects on nontradi-
tional biomarkers of cardiovascular disease, suggesting
the presence of antiatherogenic effects [79], and treating
impaired glucose tolerance patients with acarbose was
associated with a significant reduction in the risk of cardi-
ovascular disease and hypertension [80]. Our present
knowledge of the multifaceted physiological functions of
interleukins allows the assumption that they play a piv-
otal role at the crossroad between glucose metabolism
and atherothrombotic processes. These facts further sup-
port the unifying etiologic theory of both ailments
emphasizing the importance of a cardiovascular diabeto-
logic approach to interleukins for future research. Target-
ing of these cytokines – in an attempt to develop
pharmacologic activators of the "good" interleukins, and
inhibitors of the "bad" ones – might provide an effective
means to simultaneously control both atherosclerosis and
diabetes mellitus.
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